Market News How it works Learn FAQ
| GPUS 0.1689 34.05% | XXII 0.1977 -8.34% | SHFS 0.1324 -61.39% | NVD 4.19 0.96% | LUCD 0.411 25.42% | SPCX 147.49 1.89% | T 20.93 -7.96% | SOXL 83.56 1.77% | NU 15.16 2.92% | NOK 8.14 3.30% | EWZ 42.59 1.77% | NVDA 210.96 -0.59% | RIME 0.106 -12.90% | INTC 86.96 1.72% | TSLG 4.87 -1.62% | AAL 12.11 -3.89% | BBD 4.07 3.04% | STLA 4.06 -4.81% | SOXS 52.46 -1.85% | RWM 14.55 0.34% | HYG 77.05 -0.06% | MYND 0.24 47.42% | BITO 10.83 -0.28% | SPDN 8.54 0.47% | YFOR 0.2236 -1.58% | RBNE 0.19 -2.56% | TQQQ 66.29 -0.20% | VZ 44.66 -1.19% | TSLL 9.76 -1.21% | SPTI 27.63 -0.11% | YMAT 2.05 6.77% | CRWV 54.235 -2.46% | INFY 12.35 -6.58% | RIG 6.41 5.43% | F 11.6 -2.85% | SQQQ 39.68 0.20% | AIOK 12.02 182.82% | ONDS 6.2 2.99% | AAPL 347.725 -0.14% | LABT 0.31 -36.67% | CDE 13.45 -3.10% | PCG 12.63 -2.70% | GRAB 2.79 -2.11% | SOFI 14.615 -1.05% | XLE 69.33 2.60% | IREN 24.905 -2.37% | QID 14.55 0.14% | RKT 11.73 -0.09% | WULF 11.32 0.00% | BE 193.3 -11.24%
EMEmmaus Life Sciences, Inc. logo

Emmaus Life Sciences, Inc. (EMMA)

Other OTC · Currency in USD
$0.06 ▼ -0.01 (-10.05%)
At close: Oct 23, 4:00 PM ET. Market closed.

Summary

Previous Close
$0.06
Open
$0.05
Day's Range
$0.05 – $0.06
52 Week Range
$0.01 – $0.09
Volume
16,885
Avg. Volume
101,746
Market Cap
$4.04M
Beta (5Y Monthly)
9.77
PE Ratio (TTM)
--
EPS (TTM)
-$0.09
Earnings Date
Nov 18, 2026
Forward Dividend & Yield
--
Ex-Dividend Date
--
1y Target Est
--

Profile: Emmaus Life Sciences, Inc.

Sector
Healthcare
Industry
Biotechnology
Full-time employees
33
CEO
Willis C. Lee

Emmaus Life Sciences, Inc. is a commercial-stage biopharmaceutical enterprise dedicated to the discovery, development, commercialization, and sale of treatments and therapies, primarily addressing rare and orphan diseases across the United States and internationally. The company's flagship product is Endari, an L-glutamine oral powder designed to mitigate the acute complications associated with sickle cell disease in patients aged five and above, covering both pediatric and adult populations. Furthermore, Emmaus maintains a collaborative arrangement with Kainos Medicine, Inc. for the preclinical advancement of Kainos' proprietary IRAK4 inhibitor, KM10544, which is being explored as a potential anti-cancer therapeutic.

Earnings

Next report: Wed, Nov 18, 2026
EPS estimate -$0.06 · Revenue est. $6.63M
DateEst.Actual
Aug 14, 2026-$0.06$0.02Beat
May 15, 2026-$0.06-$0.05Beat
Mar 30, 2026$0.01-$0.03Miss
Nov 14, 2025–-$0.03
Aug 14, 2025$0.01-$0.02Miss
May 15, 2025–-$0.04

Get free alerts on EMMA and big market moves

Free special alerts by text & email on new investment opportunities, buyouts and the stocks moving most, in plain English.
Get free stock alerts →
Data: Financial Modeling Prep. For information only, not investment advice.